IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Immuneering Announces Positive Topline Results from Ph 1/2a Trial of IMM-1-104
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
Fast Track designation has the potential to accelerate lead asset IMM-1-104™s path to U.S. FDA submission for pancreatic ductal adenocarcinoma Company expects multiple readouts from its Phase...
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of...